A carregar...
Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia
Recent studies suggest that JAK2 serves as a novel therapeutic target in Bcr-Abl+ chronic myelogenous leukemia (CML). We have reported the existence of an HSP90- associated high molecular weight network complex (HMWNC) that is composed of HSP90 client proteins BCR-ABL, JAK2, and STAT3 in wild type B...
Na minha lista:
| Publicado no: | Genes Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4979592/ https://ncbi.nlm.nih.gov/pubmed/27551334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/genesandcancer.111 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|